Clinical Trial Update: Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating the efficacy and safety of adding gemigliptin 50 mg once daily to ongoing glimepiride as a fixed-dose combination in adults with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Gemigliptin (gemigliptin)
• Glimepiride (glimepiride)

Snippet

Sponsor: LG Life Sciences | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: UNKNOWN